Trial Profile
A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, and Pharmacokinetics After Multiple-dose Administration of 25 mg Aprocitentan in Healthy Japanese and Caucasian Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Aprocitentan (Primary)
- Indications Cardiovascular disorders; Hypertension; Resistant hypertension
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 16 Oct 2018 Status changed from recruiting to completed.